NASDAQ:CGENCompugen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.31 +0.39 (+2.80 %) (As of 05/25/2020 02:21 PM ET) Add Compare Share Today's Range$13.80Now: $14.31▼$14.3850-Day Range$6.97MA: $12.40▼$15.5852-Week Range$2.73Now: $14.31▼$16.31Volume676,114 shsAverage Volume1.50 million shsMarket Capitalization$979.09 millionP/E RatioN/ADividend YieldN/ABeta2.87 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingCompugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.67, Compugen has a potential upside of 30.4% from its current price of $14.31.Amount of Analyst CoverageCompugen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.6 Community Rank Outperform VotesCompugen has received 276 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCompugen has received 250 “underperform” votes. (Add your “underperform” vote.)Community SentimentCompugen has received 52.47% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote “Outperform” if you believe CGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCompugen does not currently pay a dividend.Dividend GrowthCompugen does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Compugen is held by insiders.Percentage Held by Institutions47.19% of the stock of Compugen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Compugen are expected to decrease in the coming year, from ($0.42) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compugen is -35.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compugen is -35.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompugen has a P/B Ratio of 19.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.62 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CGEN Previous Symbol CUSIPN/A CIK1119774 Webwww.cgen.com Phone972-3765-8585Debt Debt-to-Equity RatioN/A Current Ratio14.04 Quick Ratio14.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$17.80 million Price / Sales55.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book19.08Profitability EPS (Most Recent Fiscal Year)($0.43) Net Income$-27,340,000.00 Net MarginsN/A Return on Equity-46.10% Return on Assets-35.88%Miscellaneous Employees89 Outstanding Shares68,420,000Market Cap$979.09 million Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:CGEN Rates by TradingView Receive CGEN News and Ratings via Email Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Compugen (NASDAQ:CGEN) Frequently Asked Questions How has Compugen's stock been impacted by COVID-19 (Coronavirus)? Compugen's stock was trading at $11.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CGEN stock has increased by 21.0% and is now trading at $14.31. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Compugen? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Compugen. When is Compugen's next earnings date? Compugen is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Compugen. How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($0.10) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.10). During the same quarter in the prior year, the firm earned ($0.14) EPS. View Compugen's earnings history. What price target have analysts set for CGEN? 6 analysts have issued 12-month price objectives for Compugen's stock. Their forecasts range from $13.00 to $28.00. On average, they anticipate Compugen's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 30.4% from the stock's current price. View analysts' price targets for Compugen. Has Compugen been receiving favorable news coverage? News stories about CGEN stock have been trending somewhat positive on Monday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Compugen earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutCompugen. Who are some of Compugen's key competitors? Some companies that are related to Compugen include Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), bluebird bio (BLUE), Halozyme Therapeutics (HALO), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), Cortexyme (CRTX) and Regenxbio (RGNX). View all competitors. What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Gilead Sciences (GILD), Novavax (NVAX), Pluristem Therapeutics (PSTI), Inovio Pharmaceuticals (INO), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Alibaba Group (BABA). Who are Compugen's key executives? Compugen's management team includes the following people: Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 52)Mr. Ari Krashin, Chief Financial & Operating Officer (Age 46)Dr. John J. Hunter Ph.D., Chief Scientific Officer (Age 56)Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 50)Dr. Zurit Levine, Sr. VP of Technology Innovation (Age 51) What is Compugen's stock symbol? Compugen trades on the NASDAQ under the ticker symbol "CGEN." Who are Compugen's major shareholders? Compugen's stock is owned by a number of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (12.22%), Nikko Asset Management Americas Inc. (12.22%), RA Capital Management L.P. (4.32%), Morgan Stanley (1.27%), Taylor Frigon Capital Management LLC (0.92%) and DAFNA Capital Management LLC (0.88%). Which major investors are selling Compugen stock? CGEN stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Taylor Frigon Capital Management LLC, Morgan Stanley, Jane Street Group LLC, UBS Group AG, BlackRock Inc., Private Advisor Group LLC, and Citigroup Inc.. Which major investors are buying Compugen stock? CGEN stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., DAFNA Capital Management LLC, Sofinnova Investments Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Phoenix Holdings Ltd., Mackenzie Financial Corp, and Advisor Group Holdings Inc.. How do I buy shares of Compugen? Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Compugen's stock price today? One share of CGEN stock can currently be purchased for approximately $14.31. How big of a company is Compugen? Compugen has a market capitalization of $979.09 million and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Compugen employs 89 workers across the globe. What is Compugen's official website? The official website for Compugen is www.cgen.com. How can I contact Compugen? Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected] This page was last updated on 5/25/2020 by MarketBeat.com Staff
